Target intelligence / Profile preview

Bcl-2-like protein 1 (Bcl-xL) (Bcl-xL)

Target
Bcl-xL
Molecular classification
Bcl-2 family protein, Apoptosis regulator
01

Overview

Bcl-2-like protein 1, commonly referred to as Bcl-xL, is a critical anti-apoptotic member of the Bcl-2 family that maintains cellular survival by preserving mitochondrial outer membrane integrity. It functions by binding and sequestering pro-apoptotic proteins, such as BAX and BAK, thereby preventing the release of cytochrome c and the subsequent activation of the caspase cascade. Overexpression of Bcl-xL is a frequent occurrence in various cancers, including lung, breast, and prostate cancers, where it contributes to tumor progression and resistance to conventional therapies. As a result, Bcl-xL has emerged as a significant therapeutic target, leading to the development of BH3 mimetics like navitoclax that disrupt its anti-apoptotic activity. Additionally, Bcl-xL is a primary target in senolytic research, as its inhibition can selectively eliminate senescent cells to potentially treat age-related diseases. A major clinical hurdle in targeting Bcl-xL is its essential role in the survival of mature platelets, meaning that systemic inhibition often results in dose-limiting thrombocytopenia. Current research is focused on overcoming this toxicity through the use of PROTACs, such as DT2216, or antibody-drug conjugates that offer more tissue-specific targeting.

Other names
BCL2L1BCLXBCL-XLBCL2LApoptosis regulator Bcl-xBcl-2-like 1
02

Mechanism of action

Bcl-xL inhibitors function as BH3 mimetics, binding to the hydrophobic groove of the Bcl-xL protein to displace pro-apoptotic BH3-only proteins or multidomain pro-apoptotic proteins like BAX and BAK, thereby triggering mitochondrial outer membrane permeabilization and apoptosis.

03

Biological functions

ApoptosisCell survivalMitochondrial membrane integrityPlatelet homeostasis
04

Disease associations

CancerSenescenceAutoimmune disease
05

Safety considerations

ThrombocytopeniaNeutropeniaGastrointestinal toxicity
06

Interacting drugs

3 more in the full profile.

07

Biomarkers

BCL2L1 mRNA expressionBcl-xL protein levelsBH3 profiling

Beyond the preview

Go deeper on Bcl-2-like protein 1 (Bcl-xL) (Bcl-xL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bcl-2-like protein 1 (Bcl-xL) (Bcl-xL).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call